Abstract
Hypertension and knee osteoarthritis (OA) are frequent comorbidities. Nonsteroidal anti-inflammatory drugs (NSAIDs) are often used to relieve pain in such patients. In the last decade selective NSAIDs are used more commonly since they lead to less gastrointestinal complications. As has been shown, the treatment with NSAIDs may cause a mild rise of arterial blood pressure (BP). The influence of selective NSAIDs on BP, particularly in hypertensive patients has still to be investigated. The aim of this study was to determine arterial BP changes in patients suffering from stable arterial hypertension and knee OA and treated with rofecoxib or nabumetone. Two groups of patients with knee OA and stable arterial hypertension received either 25 mg rofecoxib once daily or namebutone 2000 mg once daily during the first week of treatment and 1000 mg for the following 3 weeks. Twenty-four hour arterial BP monitoring was performed prior to initiation of treatment and at the end of a 4-week period. The results were that no changes were found in the mean systolic and diastolic characteristics of BP in the rofecoxib treatment group during day time (delta systolic BP −0.4 mm Hg and delta diastolic BP −0.4 mm Hg), while nocturnal BP increased significantly: delta systolic BP +15.7 mm Hg and delta diastolic BP +8.5 mm Hg. The mean systolic arterial pressure in the nabumeton group raised delta systolic BP 2.9 mm Hg in the daytime and 5 mm Hg during the night-time after the treatment. The mean diastolic arterial pressure also rose delta diastolic 3.2 mm Hg and 4.9 mm Hg at day and night hours respectively. In conclusion rofecoxib treatment did not change arterial BP during day time hours, however, there was a distinct increase in night-time systolic and diastolic BP leading to a disappearance of the physiological diurnal variation. Nabumetone caused a moderate increase of day and night BP, without changes in biological diurnal variation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aalykke C, Lauritsen K . Epidemiology of NSAID-related gastroduodenal mucosal injury Best Pract Res Clin Gastroenterol 2001; 15: 705–722
Brooks P et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 Rheumatology 1999; 38: 779–788
Fitzberald GA, Patrono C . The Coxibs, selective inhibitors of cyclooxygenase-2 N Engl J Med 2001; 345: 433–442
Bayle EA, Freeman PC . Nabumetone (BRL 147777),4-(6-methoxy-2-naphtyl-butan-2-one): a new antiinflammatory agent J Pharm Pharmacol 1982; 34: 562–569
Creb WH . Endoscopic studies of nabumetone (Relifex) inpatients with rheumatoid arthritis: a comparative endoscopic and histologic evaluation Am J Med 1987; 83 (Suppl 4B): 19–24
Roth SH . Endoscopy-controlled study of the safety of nabumetone (Relifex) compared with naproxen in arthritis therapy Am J Med 1987; 83 (Suppl 4B): 25–30
Bombardier C et al. Comparison of gastrointestinal toxicity of rofecoxib and naproxen inpatients with rheumatoid arthritis N Engl J Med 2000; 343: 1520–1529
Brook RD, Kramer MB, Blaxall BC, Bisognano JD . Nonsteroidal Anti-Inflammatory Drugs and Hypertension J Clin Hypertens (Greenwich) 2000; 2: 319–323
O'Brien E, Atkins N, Staessen J . State of the market. A review of ambulatory blood pressure monitoring devices Hypertension 1995; 26: 835–842
Clive DM, Stoff JS . Renal syndromes associated with nonsteroidal antiinflammatory drugs N Engl J Med 1984; 310: 563–572
Aiken JW, Vane JR . Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin J Pharmacol Exp Ther 1973; 184: 678–687
Jonson AG et al. Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1 J Hum Hypertens 1996; 10: 257–261
Johnson AG, Nguyen TV, Day RO . Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis Ann Intern Med 1994; 121: 289–300
Pope JE, Anderson JJ, Felson DT . A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure Arch Intern Med 1993; 153: 477–484
Morgan TO, Anderson A, Bertam D . Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril Am J Hypertens 2000; 13: 1161–1167
Brown J, Dollery C, Valdes G . Interaction of nonsteroidal anti-inflammatory drugs with antihypertensive and diuretic agents. Control of vascular reactivity by endogenous prostanoids Am J Med 1986; 81: 43–57
McKenney JM et al. Effect of high-dose ibuprofen on 14-hour blood pressure in healthy women Drug Intell Clin Pharm 1987; 21: 517–521
Muscara MN et al. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence Br J Pharmacol 2000; 129: 1423–1430
Graves JW, Ingebog A, Hunder RN . Worsening of hypertension by Cyclo-oxygenase-2 inhibitors J Clin Hypertens 2000; 2: 396–398
Muller JE . Morning increase of onset of myocardial infarction. Implications concerning triggering events Cardiology 1989; 76: 96–104
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Reitblat, T., Zamir, D., Estis, L. et al. The different patterns of blood pressure elevation by rofecoxib and nabumetone. J Hum Hypertens 16, 431–434 (2002). https://doi.org/10.1038/sj.jhh.1001411
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001411